{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:16:13Z","timestamp":1768457773967,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1124\/dmd.114.062620","type":"journal-article","created":{"date-parts":[[2015,1,17]],"date-time":"2015-01-17T10:15:31Z","timestamp":1421489731000},"page":"523-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-5488","authenticated-orcid":false,"given":"Faraz","family":"Kazmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna E","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis","family":"Yerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.062620_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/tx900105n","article-title":"Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition","volume":"22","author":"Baer","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.114.062620_bib2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","article-title":"CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes","volume":"64","author":"Bahadur","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/dmd.114.062620_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-200241001-00006","article-title":"Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole","volume":"41","author":"Banfield","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1124\/dmd.114.062620_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-200241001-00005","article-title":"Lack of clinically relevant interaction between desloratadine and erythromycin","volume":"41","author":"Banfield","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.062620_bib5","first-page":"1173","article-title":"In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes","volume":"29","author":"Barecki","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","article-title":"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide","volume":"56","author":"Bidstrup","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/03602532.2014.924962","article-title":"Biotransformation and bioactivation reactions of alicyclic amines in drug molecules","volume":"46","author":"Bolleddula","year":"2014","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.114.062620_bib8","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1158\/0008-5472.CAN-07-2245","article-title":"Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062620_bib9","first-page":"838","article-title":"Species differences in N-glucuronidation","volume":"26","author":"Chiu","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib10","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/lary.24134","article-title":"Does desloratadine alter the serum levels of montelukast when administered in a fixed-dose combination?","volume":"123","author":"Cingi","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1124\/dmd.114.062620_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/carcin\/20.10.1963","article-title":"Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides","volume":"20","author":"Ciotti","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.114.062620_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.114.062620_bib13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/dmd.104.002097","article-title":"Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8","volume":"33","author":"Delaforge","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00003088-200847040-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review","volume":"47","author":"Devillier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.062620_bib15","first-page":"19","article-title":"Kinetic parameters of human P450 isoforms involved in the metabolism of the antiallergic drug, loratadine","volume":"2","author":"Dridi","year":"2013","journal-title":"Int J Bio Biol Sci"},{"key":"10.1124\/dmd.114.062620_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/00498254.2010.487163","article-title":"Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions","volume":"40","author":"Gao","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062620_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/187231209789352067","article-title":"Metabolism of loratadine and further characterization of its in vitro metabolites","volume":"3","author":"Ghosal","year":"2009","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.114.062620_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/bdd.405","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine","volume":"25","author":"Ghosal","year":"2004","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.062620_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/0091270004269518","article-title":"Pharmacokinetics\/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers","volume":"44","author":"Gupta","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0149-2918(01)80049-7","article-title":"Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study","volume":"23","author":"Gupta","year":"2001","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.114.062620_bib21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0091270007306561","article-title":"Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment","volume":"47","author":"Gupta","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/bdd.1770","article-title":"Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males","volume":"33","author":"Hakooz","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.062620_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1742-7843.2010.00543.x","article-title":"Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel","volume":"107","author":"Hanioka","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"Suppl 65","key":"10.1124\/dmd.114.062620_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1398-9995.2001.00101.x","article-title":"The pharmacologic profile of desloratadine: a review","volume":"56","author":"Henz","year":"2001","journal-title":"Allergy"},{"key":"10.1124\/dmd.114.062620_bib25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1124\/dmd.105.003830","article-title":"Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population","volume":"33","author":"Hichiya","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00726-010-0743-8","article-title":"Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8","volume":"40","author":"Jiang","year":"2011","journal-title":"Amino Acids"},{"key":"10.1124\/dmd.114.062620_bib27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1124\/dmd.113.051565","article-title":"Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4","volume":"41","author":"Kato","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/00498254.2013.878814","article-title":"In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential","volume":"44","author":"Kazmi","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062620_bib29","article-title":"Assessment under initial rate conditions of the selectivity and time course of cytochrome P450 inactivation in pooled human liver microsomes and hepatocytes: Optimization of inhibitor conditions used for reaction phenotyping studies","author":"Kazmi","year":"2014","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.114.062620_bib30","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1124\/dmd.105.004010","article-title":"Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide","volume":"33","author":"Kochansky","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.102.038992","article-title":"Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide","volume":"303","author":"Kumar","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062620_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1472-8206.2004.00254.x","article-title":"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans","volume":"18","author":"Molimard","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib33","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/carcin\/bgu191","article-title":"Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic\/racial groups","volume":"35","author":"Murphy","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.114.062620_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib35","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/dmd.111.038596","article-title":"An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes","volume":"39","author":"Parkinson","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","article-title":"The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes","volume":"199","author":"Parkinson","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib37","series-title":"Casarett & Doull's Toxicology: The Basic Science of Poisons","first-page":"185","article-title":"Biotransformation of xenobiotics","author":"Parkinson","year":"2013"},{"key":"10.1124\/dmd.114.062620_bib38","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-3565(25)12938-8","article-title":"Identification of the human P450 enzymes involved in lansoprazole metabolism","volume":"277","author":"Pearce","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062620_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14740338.5.2.211","article-title":"Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety","volume":"5","author":"Prenner","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/dmd.114.062620_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00498250500038906","article-title":"Metabolism and excretion of loratadine in male and female mice, rats and monkeys","volume":"35","author":"Ramanathan","year":"2005","journal-title":"Xenobiotica"},{"issue":"S2","key":"10.1124\/dmd.114.062620_bib41","first-page":"160","article-title":"Metabolism and excretion of desloratadine (Clarinex\u00ae) in mice, rats, monkeys and humans","volume":"38","author":"Ramanathan","year":"2006","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.114.062620_bib42","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/00498250701463325","article-title":"Disposition of desloratadine in healthy volunteers","volume":"37","author":"Ramanathan","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062620_bib43","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/ac9911692","article-title":"Liquid chromatography\/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds","volume":"72","author":"Ramanathan","year":"2000","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.114.062620_bib44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062620_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.104.002766","article-title":"Selective inhibition of human cytochrome P4502C8 by montelukast","volume":"33","author":"Walsky","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062620_bib46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000237063","article-title":"Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine","volume":"107","author":"Yumibe","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1124\/dmd.114.062620_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-2952(95)02169-8","article-title":"Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6","volume":"51","author":"Yumibe","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.062620_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.109.030981","article-title":"Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine","volume":"38","author":"Zhou","year":"2010","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624102784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624102784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.062620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:26:18Z","timestamp":1739906778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624102784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0090955624102784"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.062620","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.062620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}